14,968 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Purchased by Natixis Advisors LLC

Natixis Advisors LLC acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 14,968 shares of the company’s stock, valued at approximately $879,000.

Several other hedge funds have also added to or reduced their stakes in APGE. Vanguard Group Inc. lifted its holdings in Apogee Therapeutics by 60.7% during the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after purchasing an additional 705,795 shares during the last quarter. American International Group Inc. lifted its stake in shares of Apogee Therapeutics by 99.9% during the 1st quarter. American International Group Inc. now owns 20,391 shares of the company’s stock valued at $1,355,000 after buying an additional 10,188 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Apogee Therapeutics during the 1st quarter valued at approximately $450,000. Kennedy Capital Management LLC bought a new position in Apogee Therapeutics in the 1st quarter worth approximately $212,000. Finally, California State Teachers Retirement System grew its stake in Apogee Therapeutics by 25.6% in the 1st quarter. California State Teachers Retirement System now owns 23,002 shares of the company’s stock valued at $1,528,000 after buying an additional 4,693 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on APGE. Wedbush restated an “outperform” rating and set a $87.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, November 12th. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday. They set a “buy” rating and a $89.00 price objective for the company. Guggenheim upped their target price on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a report on Monday. They issued a “buy” rating and a $89.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $83.50.

Apogee Therapeutics Price Performance

Shares of APGE opened at $44.70 on Thursday. Apogee Therapeutics, Inc. has a 1-year low of $16.39 and a 1-year high of $72.29. The company has a market capitalization of $2.01 billion, a P/E ratio of -18.41 and a beta of 2.93. The firm’s 50 day simple moving average is $54.01 and its 200 day simple moving average is $48.57.

Insider Activity

In related news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90. Following the transaction, the insider now owns 274,128 shares of the company’s stock, valued at approximately $15,422,441.28. This trade represents a 2.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,394,487 shares of the company’s stock, valued at $66,405,470.94. This represents a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 114,995 shares of company stock worth $6,128,295. 36.10% of the stock is currently owned by corporate insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.